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Abstract: The aim of this contribution was to evaluate the impact of processing methods and polymeric
carriers on the physicochemical properties of solid dispersions of the poorly soluble drug progesterone
(PG). Five polymers: hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate
succinate (HPMCAS), microcrystalline cellulose (MCC), polyvinylpyrrolidone (PVP) and silica (SiO2),
and two processing methods: solvent evaporation (SE) and mechano-chemical activation by co-milling
(BM) were applied. H-bonding was demonstrated by FTIR spectra as clear shifting of drug peaks
at 1707 cm−1 (C20 carbonyl) and 1668 cm−1 (C3 carbonyl). Additionally, spectroscopic and thermal
analysis revealed the presence of unstable PG II polymorphic form and a second heating DSC
cycle, the presence of another polymorph possibly assigned to form III, but their influence on
drug solubility was not apparent. Except for PG–MCC, solid dispersions improved drug solubility
compared to physical mixtures. For SE dispersions, an inverse relationship was found between drug
water solubility and drug–polymer Hansen solubility parameter difference (∆δt), whereas for BM
dispersions, the solubility was influenced by both the intermolecular interactions and the polymer
Tg. Solubility improvement with SE was demonstrated for all except PG–MCC dispersions, whereas
improvement with BM was demonstrated by the PG–HPMC, PG–PVP and PG–HPMCAS dispersions,
the last showing impressive increase from 34.21 to 82.13 µg/mL. The extensive H-bonding between
PG and HPMCAS was proved by FTIR analysis of the dispersion in the liquid state. In conclusion,
although SE improved drug solubility, BM gave more than twice greater improvement. This indicates
that directly operating intermolecular forces are more efficient than the solvent mediated.
Keywords: solid dispersions; mechano-chemical activation; saturation solubility; thermal analysis;
Flory–Huggins; Hansen solubility parameters
1. Introduction
Poor aqueous solubility has always been a challenge in the development of hydrophobic drugs
for oral delivery [1,2]. One potential solution has been the use of solid dispersions in which the
hydrophobic drug is mixed at molecular level with a hydrophilic carrier. Molecular interactions such
as hydrogen bonding can be optimized by careful choice of the preparation conditions [3]. While
enhancement in solubility could be attributed to transformation of the drug to amorphous state,
the nature of carrier was also shown to have a major impact on dissolution [1,4]. Although nowadays
state of the art mechnanochemical methods such as hot-melt extrusion are exploited for their ability to
enhance drug release in conjunction with polymers, there are only a few reports for their application
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to progesterone, e.g., reservoir systems of progesterone loaded into polymeric matrix for controlled
release [5]. Mechano-chemical activation is often applied by dry or wet milling and is used to enhance
the solubility and dissolution rate of poorly soluble drugs [3,6]. This is usually applied by co-milling
drug with excipients and is commonly used for particle size reduction. It has the advantage of avoiding
solvent use, thus simplifying the process compared with solvent-based methods such as spray drying
or freeze-drying [4].
The main drawback of mechano-chemical activation is the heterogeneous nature of collisions
between drug and excipients during co-milling, which may lead to large batch-to-batch variations [7].
While a number of studies have been conducted on aqueous solubility using mechano-chemical
activation, the issue of variability in the resulting drug solubilities has been overlooked [8]. An important
question is what is the impact of the processing method (co-milling vs. solvent evaporation) on
molecular interactions. The answer to this question will aid a better understanding of both these
processes, optimization of the applied conditions and minimization of batch-to-batch variation. In
general, differences are expected between the two methods since mechano-chemical activation involves
heat/collisions, whereas solvent evaporation involves solvent-mediated interactions. The use of
these methods is common for preparation of solid dispersions. PG solid dispersions with Pluronic,
polyethylene glycol and polyvinylpyrrolidone were previously prepared via solvent evaporation and
were found to improve solubility and vaginal permeability [9]. In a different study, PG solid dispersion
with Pluronic 127 were formulated as mucoadhesive vaginal tablets and were found to improve vaginal
drug delivery with minimum side effects [10].
In this study, solid dispersions of progesterone (PG) used as a poorly water-soluble model drug
were prepared by solvent evaporation and mechano-chemical activation. PG is an endogenous steroid
hormone involved in the menstrual cycle, pregnancy and embryogenesis [11]. Oral administration
of PG has proven ineffective due to its poor aqueous solubility, 7 µg/mL at 25 ◦C, and extensive
first-pass metabolism [12,13]. Despite attempts by formulation scientists to improve its solubility via
micronization or oil-based dispersions [14–17], these formulations could only achieve a bioavailability
of <10% owing to PG’s first-pass metabolism [18]. Thus, large doses, typically, 100, 200 and 300 mg,
are required, which have been associated with low tolerance in patients. Therefore, improvement of
PG solubility was attempted by co-processing with different polymeric excipients and application of
solvent evaporation and co-milling.
Five excipients were compared: hydroxypropyl methylcellulose (HPMC), hydroxypropyl
methylcellulose acetate succinate (HPMCAS), microcrystalline cellulose (MCC), polyvinylpyrrolidone
(PVP) and silica (SiO2). They were selected on the basis of their different molecular characteristics:
HPMC, HPMCAS and PVP are amorphous but PVP does not have H-bond donor groups, whereas the
other two polymers have, MCC is semicrystalline with H-bond donors, and silica is amorphous with
an ability to accept protons and form H-bonds [19]. In addition, these polymers are commonly used
excipients for oral drug delivery, and enhancement of aqueous solubility based on these polymers will
be of great interest to pharmaceutical formulation scientists. The hydrophilic nature of those polymers
dictates their ability to increase dissolution and wettability of hydrophobic drugs. Drug–excipient
interactions in the solid dispersions were elucidated experimentally using thermal and spectroscopic
analysis and also theoretically, using Hansen solubility parameters and Flory–Huggins analysis.
Parameters of these models were calculated as predictors of the miscibility of progesterone with the
examined polymers (Figure 1).
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2. Materials and Methods
2.1. Materials
Progesterone (PG) was obtained from Sigma Aldrich (Dorset, UK). Hydroxypropyl methylcellulose
acetate succinate (HPMCAS grade HF, average MW 20,000 Da) was gifted by Shin-Etsu (Tokyo, Japan).
Polyvinylpyrrolidone (PVP K30, average MW 40,000 Da), silicon dioxide (SiO2), hydroxypropyl
methylcellulose (hypromellose, HPMC) (viscosity range of 3000–5600), microcrystalline cellulose
(MCC) and deuterium oxide (D2O) were obtained from Sigma Aldrich (Gillingham, UK). All other
solvents were obtained from VWR International (Leicestershire, UK). All chemicals were of analytical
grade and were used as received. Chemical structures of the experimental drug and polymers are
presented in Figure 1.
2.2. Methods
2.2.1. Preparation of PG Solid Dispersions Using Solvent Evaporation
Mixtures of PG with each polymeric excipient were prepared using 1 g drug/polymer samples
at ratio 3:1. Due to limited solubi ity of some of the polymers, higher polymer/drug ratios requir d
high s lvent volumes making the process unpractical. The samples were dissolved in 50 mL acetone
under agita ion for 20 in and then transferred to a round-bottom flask. Acet ne was removed usi g
a Rotavapor (BUCHI Rotavapor® R-300, Flawil, Switzerland) at 40 ◦C. ft r evaporation, the solids
retained in the flask were dried under vacuum for fu ther 24 h to eliminat ny residual solvent.
The resultant solid mass was ground for 10 min and passed t rough 80 µm sieve.
2.2.2. Preparation of PG Solid Dispersions Using Mechano-chemical Activation
Mixtures of PG with each polymeric excipient were prepared using 1 g samples at drug/polymer
weight ratio of 1:3 which was previously found optimal for enhancing stability of amorphous PG [20].
The mixtures were transferred into 10 mL zirconiu oxide lined grinding jars containing one 12 mm
diameter aluminium oxide ceramic milling ball and milled at a frequency of 30 s−1 for 5 min using
a Retsch MM200 mill (Castleford, UK). The product was collected and sieved with an 80 µm orifice sieve.
2.2.3. Preparation of Physical Mixtures
Physical mixtures of PG with each polymer at ratios corresponding to those used in the PG–polymer
dispersions were prepared by mixing for 10 min in a Turbula mixer (Bachofen, Switzerland).
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2.2.4. Differential Scanning Calorimetry (DSC)
Samples of 5–10 mg were placed in sealed aluminium pans and scanned using a differential
scanning calorimeter (DSC) (TA instruments, New Castle, DE, USA) at a heating rate of 10 ◦C/min,
from 25 ◦C to 230 ◦C. The method started with isothermal hold at 90 ◦C for 10 min. Melting points and
heats of fusion were determined.
From the heat of fusion of the pure drug (∆Ho), considered as 100%, and the heat of fusion of
the drug from dispersion (∆Hf), the crystallinity (Xc) was calculated according to Equation (1) for SE
dispersions and Equation (2) for BM dispersions.
Xc (%) = [(∆Hf)/(0.75)]/∆Ho)) × 100 (1)
Xc (%) = [(∆Hf)/(0.25)]/∆Ho)) × 100 (2)
2.2.5. Fourier-Transform Infrared Spectroscopy (FTIR) for Solid Dispersions
Solid dispersions and physical mixtures were analysed by FTIR spectroscopy to identify
hydrogen bonding. Spectra were collected using a Perkin–Elmer Spectrum One (Waltham, MA,
USA) spectrophotometer, operated in attenuated total reflectance mode. Samples were placed on
germanium crystal and scanned over the wavelength range of 4000–550 cm−1 at a resolution of 4 cm−1.
2.2.6. FTIR Studies of Solid Dispersions Dissolved in D2O and Methanol
In certain cases, FTIR spectra of solid dispersions were also obtained after dissolving the dispersions
in methanol and D2O in order to confirm the existence of H-bonding between drug and polymer in the
absence of water peaks. A Perkin–Elmer Spectrum One spectrometer (Waltham, MA, USA) was used,
and spectra of the dissolved samples were collected with the aid of an Omni infrared cell with calcium
fluoride windows (Sigma Aldrich, Dorset, UK). Scans were collected over the wavelength range of
4000–1100 cm−1 at a resolution of 4 cm−1.
2.2.7. Solubility Studies
The equilibrium solubility of PG from solid dispersions and physical mixtures in phosphate buffer
was determined. Solubility of neat PG was also determined for comparison. Samples containing
the equivalent of 10 mg PG were placed in microcentrifuge tubes containing 1 mL phosphate buffer
and mixed using a rotary mixer (Bibby Scientific Limited, Staffordshire, UK) at room temperature
(~22 ◦C) for 72 h. The drug-saturated samples were subsequently centrifuged (Heraeus Biofuge Pico,
Germany) at 13,000 rpm (16,060× g) for 10 min after which the supernatant was removed and analysed.
The dissolved drug was quantified by UV spectrophotometry using a standard calibration curve
measured for absorbance at 245 nm. All measurements were performed in triplicate, and mean and
standard deviation were calculated.
2.2.8. Drug–Polymer Miscibility
Solubility Parameters
The total solubility parameter, δt, represents the total attractive forces in a condensed matter and
can be expressed as the square root of the sum of Hansen solubility parameters (HSPs)
δt = (δd2 + δp2 + δhb2)1/2 (3)
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where δd accounts for the dispersion forces, δp for the polar forces, and δhb for hydrogen-bonding
attraction [21]. HSPs for progesterone and HPMCAS were calculated according to the group contribution
method of [22] using the following equations applicable to values greater than 3 MPa(1/2):
δd = (
∑
iNiCi + 959.11)0.4126 (4)
δp =
∑
iNiCi + 7.6 (5)
δhb =
∑
iNiCi + 7.7 (6)
where, Ci is the contribution of chemical group i occurring Ni times in the molecule and δhb includes
all forms of electron exchange.
For progesterone, the first-order contributing groups are: CH3–, –CH2–, –CH=, >C<, >C=O and
–CH=C<–COOH and the second order group is Ccyclic=O (Figure 1). For HPMCAS, the first-order
contributing groups are: –CHO–, –CH<, –CH2–, –OH, CH3COO–, –CH2COO–, –CH2-, –COOH,
–OCH3, –CH3, –CH<, OH and –CH2O (Figure 1). Occurrences are shown in Table 1. For HPMCAS, they
were calculated by taking into account the substitutions in the glucopyranose unit which according
to the manufacturer’s data (HPMCAS grade HF) were for the hydroxy (OH) group 50%, the acetyl
(–OCH2COCH3) group 12%, the succinyl (–OCOCH2CH2COOH) group 6%, the methoxy (–OCH3)
group 24% and the hydroxy proxy (–OCH2CH(OH)CH3) group 8%. Since there are six hydroxyls
per glucopyranose unit, half of which is available for esterification (manufacturer’s data), three of
HPMCAS –OH are esterified and three are not. Therefore, the occurrences for the substituting groups
were for acetyl group 0.36 (= 12% × 3), for succinyl group 0.18 (= 6% × 3), for methoxy group 0.72 (=
24% × 3) and for hydroxy proxy group 0.24 (= 8% × 3). Group occurrences and computations of Hansen
solubility parameters for PG and HPMCAS are given in Table 1. Calculated solubility parameters for
PG and HPMCAS and literature values for HPMC, MCC, PVP and SiO2 [23,24] are given in Table 2.
Flory–Huggins Thermodynamic Analysis
For the determination of enthalpy, entropy and energy of mixing, the Flory–Huggins model was
applied [20,25,26]. ∆GM is the free energy of mixing for ndrug and npolyner moles, respectively, present
at Φdrug and Φpolymer volume fractions. The interaction parameter χ accounts for the enthalpy of
mixing. It can be calculated from Equation (8) and then substituted into Equation (7) to find the free
energy of mixing [20].
∆GM
RT
= ndruglnΦdrug + npolymerlnΦpolymer + χndrugΦpolymer (7) 1TmixM − 1TpureM
 = −R∆Hfus [lnΦdrug +
(
1− 1
m
)
Φpolymer + χΦpolymer
2 (8)
where TmixM and T
pure
M are the melting temperatures of the drug in the presence of polymer and alone,
respectively, ∆Hfus is the enthalpy of mixing of pure drug, and m is the ratio of the polymer to drug
volume (calculated as molar volumes from the true density).
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Table 1. Computation of Hansen solubility parameters (MPa1/2) for progesterone and hydroxypropyl
methylcellulose acetate succinate (HPMCAS).
Progesterone Group Contributions (Ci’s) Occurrences NiCi
First-Order Groups δd’ δp’ δhb’ Ni δd’ δp’ δhb’
CH3– −123.01 −1.6444 −0.7458 3 −369.03 −4.9332 −2.2374
–CH2- 1.82 −0.3141 −0.3877 9 16.38 −2.8269 −3.4893
–CH< 82.94 0.6051 −0.2064 3 248.82 1.8153 −0.6192
>C< 182.13 2.0249 −0.0113 2 364.26 4.0498 −0.0226
>C=O −127.16 0.7691 1.7033 1 −127.16 0.7691 1.7033
–CH=C< 62.48 −1.1018 −1.7171 1 62.48 −1.1018 −1.7171
ΣNiCi: 195.75 −2.23 −6.38
Second-Order Groups δd” δp” δhb” Mj δd” δp” δhb”
Ccyclic=O −46.57 0.1972 −0.4496 1 −46.57 0.1972 −0.4496
ΣMjDj: −46.57 0.1972 −0.4496
HPMCAS Group Contributions (Ci’s) Occurrences NiCi
First-Order Groups δd’ δp’ δhb’ (Ni) δd’ δp’ δhb’
–CHO- 111.46 1.6001 0.4873 2 222.92 3.2002 0.9746
–CH< 82.94 0.6051 −0.2064 3 248.82 1.8153 −0.6192
–CH2– 1.82 −0.3141 −0.3877 1 1.82 −0.3141 −0.3877
–OH −29.97 1.0587 7.3609 1.5 −44.96 1.5881 11.0414
CH3COO– −53.86 −0.6075 1.7051 0.36 −19.39 −0.2187 0.6138
–CH2COO– 89.11 3.4942 1.3893 0.18 16.04 0.6290 0.2501
–CH2– 1.82 −0.3141 −0.3877 0.18 0.33 −0.0565 −0.0698
–COOH −38.16 0.7153 3.8422 0.18 −6.87 0.1288 0.6916
–OCH3 −68.07 0.0089 0.2676 0.72 −49.01 0.0064 0.1927
–CH3 −123.01 −1.6444 −0.7458 0.24 −29.52 −0.3947 −0.1790
–CH< 82.94 0.6051 −0.2064 0.24 19.91 0.1452 −0.0495
–OH −29.97 1.0587 7.3609 0.24 −7.19 0.2541 1.7666
–CH2O– 13.4 0.8132 −0.1196 0.24 3.22 0.1952 −0.0287
ΣNiCi: 356.11 6.98 14.20
Table 2. Hansen solubility parameters (MPa)1/2 and glass transition temperatures.
Material δd δp δhb δt ∆δt (MPa)1/2 Tg (◦C)
Progesterone 18.0 5.6 0.9 18.9 – 10
HPMC 18.0 15.3 19.4 30.6 11.7 162
HPMCAS 19.4 14.6 21.9 32.7 13.8 120
MCC 19.4 12.7 31.3 39.3 20.4 143
PVP 17.4 0.6 8.6 19.4 0.5 168
SiO2 19.4 7.5 6.7 21.9 3.0 250
3. Results and Discussion
From the chemical structures shown in Figure 1, the ability for H-bonding between drug and
polymers can be deduced. HPMC and HPMCAS form H-bonds by offering protons and have been
found to produce solid dispersions with improved drug solubility [19]. MCC has H-bond donors and
has been found to increase ibuprofen solubility and dissolution by co-milling with the drug [27]. PVP
has proton accepting carbonyl group and less strong accepting N atom and can act both as solubilizer
and crystallization inhibitor [28]. Silica can accept protons to form H-bonds and has been found to
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improve the solubility and dissolution of drugs by co-milling, the extent of which depends on whether
dry or wet co-milling is applied [29].
3.1. Hansen Solubility Parameters
Hansen solubility parameters (HSPs) were calculated as an indication of miscibility of the solid
dispersion components. The total solubility parameter, δt, is a measure of the attractive intermolecular
forces in the material. Materials with similar δt values are considered miscible or that one can dissolve
in the other. Therefore, comparison of δt values can be used to predict miscibility of PG with the
examined polymers [30]. From the values given in Table 2, it can be seen that the contribution of
dispersive forces (δd) is similar for all materials, but the polar (δp) and H-bonding (δhb) components are
different, with cellulose-based excipients showing higher δp, δhb and hence, higher δt values (from 30.6
to 39.3 MPa1/2 compared with 18.9 to 21.9 MPa1/2). Consequently, the differences in ∆δt between drug
and polymers varied and were low for PVP and SiO2 (0.5 and 3.0 MPa0.5, respectively), intermediate
for the cellulose ethers HPMC and HPMCCAS (11.7 and 13.8 MPa0.5, respectively), but high for MCC
(20.4 MPa0.5).
Overall, the results of HSPs point to good drug miscibility with PVP and SiO2, low miscibility
with the cellulose ethers and no miscibility with MCC. These results should reflect in the intermolecular
interactions during preparation of solid dispersions by solvent evaporation, since both drug and
polymer are in a dissolved state, free to interact. However, in the case of mechano-chemical activation,
interactions are also governed by the degree of surface melting and creation of molten surface areas
which is a prerequisite for the operation of intermolecular forces.
Hansen solubility parameters were computed in this work: for progesterone and HPMCAS
according to Stefanis and Panayiotou 2008 [22]; for HPMC and MCC from Archer 1992 [24]; for PVP
from Kolter et al. 2012 [31] and for SiO2 from Tsutsumi et al. 2019 [23].
Tg (glass transition temperature) was computed: for progesterone from Koutsamanis et al., 2020 [5];
for HPMC from Shin-Etsu Technical information manual; for HPMCAS and PVP from Lehmkemper et
al. 2018 [32] and for MCC from Szczesniak et al. 2008 [33].
3.2. Spectroscopic Analysis of PG Solid Dispersions
3.2.1. Drug–Polymer Interactions
Figure 2 presents FTIR spectra of PG and PG solid dispersions prepared by solvent evaporation
(SE) and co-milling (BM). PG shows two characteristic peaks at 1707 cm−1 (first from the left) and
1668 cm−1 (second from the left) corresponding to stretching vibration of carbonyl groups at C20 and
C3, respectively (Figure 1). The C3 carbonyl is highly basic and can form more than two H-bonds
because of adjacent conjugation conferring the oxygen a negative charge as well as the available space
for additional bond [34]. Therefore, the C3 carbonyl has major role in intermolecular H-bonding.
This also depends on the presence of excess hydrogen bond donors, as it is the case with HPMCAS
and HPMC.
As it can be seen in Figure 2, overall, the peaks of PG obtained from both SE and BM dispersions are
shifted to lower wavenumbers (lower frequencies), which is attributed to H-bonding. The PG–HPMC
dispersion from SE shows clear shift of the 1668 cm−1 peak (C3 carbonyl) to 1663 cm−1 but only
a minimal shift of the 1707 cm−1 peak to 1705 cm−1 appearing as shoulder, implying that at C20,
the molecule remains as unbounded ketone. Conversely, the PG–HPMC dispersion from BM shows
clear shifts at both peak positions (from 1707 to 1699 and from 1668 cm−1 to 1662 cm−1), indicating
greater H-bonding interaction. For the PG–HPMCAS and PG–MCC dispersions prepared by both SE
and BM methods, shifts appear in both C3 and C20 groups. A broad vibration at 1737 cm−1 could be
seen due to the C=O group of HPMCAS-PG prepared by BM, whereas it slightly shifted to 1739 cm−1
in HPMCAS-PG prepared by SE.
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Figure 2. FTIR spectra of PG solid ersions prepared by sol ent evaporation (SE) and bead
co-milling (BM) compared with the spectrum of pure drug (progesterone, PG), showing changes in the
carbonyl group stretching vibration region (indicated by dotted lines). Peak shifts reflect intermolecular
interactions due to the processing method.
In the case of PG–PVP and PG–SiO2 dispersions and for both SE and BM methods, the spectra show
broad, shifted peaks. PVP and SiO2 are hygroscopic and contain up o 10% w/w water under normal
environmental conditions [35]. Since they contain only proton-accepting groups, direct H-bonding
is not possible. Therefore, the shift in the PG–PVP dispersions should be attributed to H-bonding
with water molecules acting as mediators between PVP and drug, whereas for PG–SiO2, it should be
attributed to SiOH . . . H2O bonding due to the association of water with surface silanol groups [36].
With a potential coordination number of C3 carbonyl up to three, water molecules may be attracted
and form bonds at C3 and to some extent, at C20.
Overall, the results of spectroscopic analysis demonstrate the ability of all the polymers to interact
with PG via H-bonding. The clear peak shifts of the PG–HPMC co-milled dispersion compared to the
corresponding SE at both carbonyl peak positions indicate greater H-bonding ability with possible
consequences of the presence of polymer on the wettability, solubility and dissolution of the drug.
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3.2.2. Polymorphism
PG has been known to exist in two polymorphic forms, I and II, that can be distinguished from
each other on the basis of their thermodynamic properties and FTIR spectra [37]. Since differences in the
physical stability and dissolution profile of the polymorphs has been reported [38], any polymorphic
transformation of PG due to co-processing is of importance. In Figure 3, FTIR spectra of solid
dispersions prepared by SE (a) and BM (b) are presented. In the BM spectra of HPMC, PVP and
SiO2, a second peak appears at 863 cm−1 (indicated with arrows) immediately after 871 cm−1 (out of
plane bending to an sp2 at C2-C4), which is characteristic of PG form II [35]. This peak is not seen
in the corresponding SE solid dispersions which show only the characteristic peak of PG form I at
871 cm−1, and also, it is not seen in any SE dispersion of the other polymers. On the basis of shifting
and absorption intensity of the peaks in Figure 3b, it appears that form II is predominant in the BM
dispersions of PG with HPMC, form I is predominant in the BM dispersions of PG with HPMCAS and
MCC, whereas both polymorphs, I and II, are present in equal amounts in the BM dispersions of PG
with PVP and SiO2. In all the SE dispersions, only form I is present.
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Figure 3. FTIR spectra of solid dispersions prepared by (a) solvent evaporation and (b) co-milling
showing polymorphic changes of PG. In the BM spectra of hydroxypropyl methylcellulose (HPMC),
polyvinylpyrrolidone (PVP) and SiO2, a second peak appears at 863 cm−1 (indicated with arrows)
immediately after 871 cm−1 (out of plane bending to an sp2 at C2-C4), which is characteristic of PG
form II.
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3.3. Thermal Analysis of PG Solid Dispersions
3.3.1. DSC of PG Solid Dispersions Prepared by Solvent Evaporation
Thermal analysis was used to confirm the two polymorphic forms seen in the FTIR spectra and
detect further thermal events. In Figure 4, thermograms of PG–polymer solid dispersions prepared by
SE are shown (thermograph for neat drug with single peak at 131 ◦C is not shown to avoid confusion).
In Table 3, results of melting points, heats of fusion and heats of crystallization after second heating
cycle are presented. Since PG exhibits polymorphism, it is not surprising to see in Figure 4 more than
one endothermic peak evolving during heating instead of the single peak of neat drug at 131 ◦C (not
shown in figure due to crowdedness). Furthermore, it is known that the melting points of the two
well-known PG polymorphs, I and II, are 129 ◦C and 122 ◦C, respectively [39–41].Polymers 2020, 12, x FOR PEER REVIEW 11 of 19 
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Table 3. Summary of the results of thermal analysis (DSC) showing melting points and heats of fusion
of polymorphs I, II and III, and heat of recrystallization of solid dispersions prepared by solvent
evaporation (SE). First heating cycle was initiated from ambient temperature to 170 ◦C followed by
cooling to ambient temperature and a second heating cycle from ambient to 170 ◦C.
Polymorph HPMC HPMCAS MCC PVP SiO2
First
heating
cycle
Melting temp.
(onset, ◦C)
I 128.3 ± 0.2 126.1 ± 1.1 129.1 ± 1.2 127.3 ± 0.7 127.3 ± 0.3
II 120 ± 0.4 118.8 ± 0.3 N/A 120.1 ± 0.4 N/A
Heat of fusion (J/g) I 73 ± 1.4 78.8 ± 1.3 83.3 ± 0.6 81.9 ± 0.5 83.1 ± 0.7
II 10.4 ± 0.9 2.1 ± 0.2 N/A 2.8 ± 0.2 N/A
Second
heating
cycle
Melting temp.
(onset, ◦C) III 107.8 ± 0.3 104.6 ± 0.8 106.4 ± 0.2 107.6 ± 0.4 100.4 ± 0.5
Crystallization temp
(onset, ◦C) – 69.9 ± 0.7 N/A 49.5 ± 0.4 N/A 53 ± 0.3
Heat of
fusion/crystallization
(J/g)
III 26.1 ±0.8/59.1 ± 1.2
0.7 ±
0.1/NA
63.1 ±
1.1/37.9 ± 1.3
18.4 ±
1.1/NA
57.6 ±
0.1/35.9 ± 0.3
To elucidate further differences in the thermal properties and reveal events that may have been
masked due to evaporating solvent, a second heating cycle was performed after cooling the molten
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samples to room temperature. Figure 4 shows the heating scan of all samples; first heating cycle was
initiated from ambient temperature to 170 ◦C followed by cooling to ambient temperature and a second
heating cycle from ambient temperature to 170 ◦C. As it can be seen in Figure 4, an exothermic peak was
formed between 40 ◦C and 100 ◦C from the reheated PG–HPMC, PG–SiO2 and PG–MCC dispersions,
implying recrystallization of amorphous drug. This peak is followed by a melting endotherm with
onset at 100–108 ◦C (Table 3), which corresponds to unstable PG form III. So far, only few studies have
reported this peak [42,43].
The impact on the solubility of recrystallization of drug to form III is not clear, e.g., such
recrystallization might happen during dissolution of PG–MCC or PG–SiO2 dispersions, which
recrystallize at low temperatures (Figure 4 and Table 2). The absence of recrystallization peak of form
III for PG–HPMCAS (Figure 4) is ascribed to HPMCAS action as nucleation inhibitor. Overall, the DSCs
of SE dispersions were eventful, showing presence of forms I and II in the dispersions with HPMCAS,
PVP and HPMC but only form I in the dispersions with SiO2 and MCC.
3.3.2. DSC of PG Solid Dispersions Prepared by Co-milling
In Figure 5, the DSCs of BM solid dispersions are shown. The melting peaks of dispersions
PG–HPMCAS, PG–SiO2 and PG–HPMC appear broad implying greater influence on structure integrity.
The melting points (Table 4) increased in the order of HPMCAS < SiO2 < HPMC < PVP < MCC, which
reflects the extent of polymer interference on PG structure. For PG–MCC, the peak at 127.4 ◦C (Table 4)
represents melting of PG form I. The peak of HPMCAS-PG should also correspond to melting of form I
despite its appearance at a markedly lower temperature of 98.2 ◦C (Table 4). This is supported by the
fact that in the FTIR spectrum of the co-milled PG–HPMCAS dispersion (Figure 3), the drug exists as
form I only. The lowering of m.p. should be attributed to interaction and structure relaxation. On the
other hand, the broad peaks of the BM dispersions with HPMC, PVP and SiO2 in Figure 5, showing
melting points at 115.4, 120.8 and 110.8 ◦C, respectively (Table 4), should result from the overlapping
of melting endotherms of forms I and II, which are present in these dispersions as shown in the FTIR
spectra (Figure 3b).
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Table 4. Melting points of solid dispersions prepared by co-milling (BM). A second cycle was run for
SE dispersions because evaporated solvent may have masked some events. There was no issue with
the BM dispersions, and for them, a second cycle was not run.
HPMC HPMCAS MCC PVP SiO2
First
Heating
Cycle
Melting temp.
(onset (◦C)) 115.4 ± 0.2 98.2 ± 0.2 127.4 ± 0.2 120.8 ± 0.3 110.8 ± 0.3
Heat of fusion
(J/g) 52.4 ± 1.4 51.2 ± 1.3 73.6 ± 0.6 58.8 ± 0.5 46.4 ± 0.7
Crystallinity (%) 62% 61% 88% 70% 55%
Compared with the SE, the melting points in the DSCs of BM dispersions are lower and the peaks
broader (compare Figures 4 and 5) suggesting greater impact on drug structure. One reason is because
of the greater amount of polymer present in the solid dispersions (drug/polymer 1:3 in the BM but
3:1 in the SE). A second reason is the high energy supplied by milling, causing local melting and
amorphization due to the absorbed heat. The crystallinities of the drug in the SE and BM dispersions
compared to neat drug calculated from Equations (1) and (2) are given in Tables 3 and 4. It can be seen
that the crystallinity of PG in the SE dispersions is greater than 96%, whereas in the BM dispersions,
it is much lower between 55% and 88%. A third reason is the direct interaction and development of
intermolecular forces instead of solvent-mediated interaction.
3.4. Solubility Studies
3.4.1. Drug Solubility from Solid Dispersions Prepared by Solvent Evaporation (SE)
The equilibrium solubility of PG from SE solid dispersions and the corresponding physical
mixtures is given in Table 5. Except for PG–MCC, all other solid dispersions improved drug solubility
compared with the physical mixtures. Among the SE dispersions, the greater increase is shown by
PG–HPMCAS (from 17.92 to 23.21 µg/mL) and PG–PVP (from 18.64 to 26.34 µg/mL), which should be
attributed to the water solubility of these polymers. During dissolution, soluble units of polymer chains
with attached drug molecules may form, facilitating drug wetting and solubility [44]. Furthermore,
from Table 5, it can be seen that dispersions with HPMC and SiO2 also improved drug solubility,
although to a lesser extent than HPMCAS and PVP, which is explained by an initial gel formation
due to the penetrating water followed by disintegration to a colloidal dispersion where the drug is
homogeneously distributed and wetted [45]. The lack of solubility improvement from the PG–MCC
dispersion indicates that despite its hydrophilic character, MCC did not assist drug wetting.
Table 5. Equilibrium solubility of progesterone (PG) (µg/mL) in water (pH 6.8) from solid dispersions
obtained by solvent evaporation (SE), corresponding physical mixtures (PM) and neat drug (PG).
Polymer HPMC HPMCAS MCC PVP SiO2
SE 16.79 ± 0.25 23.21 ± 0.92 10.99 ± 0.52 26.34 ± 1.64 24.29 ± 5.26
PM 13.95 ± 0.59 17.92 ± 0.58 10.37 ± 0.87 18.64 ± 2.55 21.48 ± 0.57
PG 11.49 ± 0.46
Since solid dispersions produced by SE evolve from dissolved drug and polymer species, their
molecules can easily interact during solidification through dispersive, polar and H-bonding forces.
This interaction should have a direct effect on drug solubility in water, since greater interaction means
stronger attachment of drug to polymer and possible formation of wetted or soluble drug–polymer
units. In Figure 6, the relationship between drug solubility in water and drug–polymer Hansen
solubility parameter difference ∆δt for dispersions and corresponding physical mixtures is examined.
Each pair of points (green and black) refers to each of the studied polymers (data extracted from
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Tables 2 and 5). Except for PG–HPMCAS, the points for the solid dispersions fall on a straight-line
confirming correlation in four out of five cases. The reason for the PG–HPMCAS point standing as
outlier (marked by arrow) might be interference of acetone in the drug–polymer interaction during
solvent evaporation. This is supported by the drug solubility vs. ∆δt plot for physical mixtures
(Figure 6) where the PG–HPMCAS point lies closer to others.
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3.4.2. Drug Solubility from Solid Dispersions Prepared by Co-milling (BM)
The solubilities of PG in water from the BM solid dispersions and the corresponding physical
mixtures are presented in Table 6. There is significant improvement over the physical mixtures for
HPCAS, HPMC and PVP which is attributed to the polymer solubility in water, facilitating wetting and
solubilization of polymer chains attached to drug molecules. The improvement is considerably greater
than the corresponding SE dispersions (compare first rows of Tables 5 and 6), indicating that BM is more
effective in promoting intermolecular drug–polymer interactions and structure alteration. In other
words, direct drug–polymer interactions operating during BM are more efficient than solvent-mediated
interactions. This is supported by the results of thermal analysis for HPCAS, HPMC and PVP in
Tables 3 and 4. BM yielded lower melting points (98.2–120.8 ◦C compared with 126.1–128.3 ◦C for
form I), lower heats of fusion (51.2–58.8 J/g compared with 73.0–81.9 J/g) and lower crystallinities
(46.4%–73.6% compared with 96%–99%) than SE. Further evidence for the greater efficiency of BM is
provided for the PG–HPMC dispersion by the FTIR spectrum in Figure 2. The shift due to H-bonding
at C20 is minimal for the SE dispersion (from 1707 to 1705 cm−1) but pronounced for the BM (from
1707 to 1699 cm−1).
Table 6. Equilibrium solubility (µg/mL) of PG from solid dispersions prepared by co-milling (BM), the
corresponding physical mixtures (PM) and neat drug (PG).
Polymer HPMC HPMCAS MCC PVP SiO2
BM 56.68 ± 2.35 82.13 ± 4.32 14.67 ± 1.31 54.42 ± 5.05 25.18 ± 0.85
PM 42.52 ± 1.53 34.21 ± 1.66 15.67 ± 0.80 50.90 ± 2.45 32.94 ± 0.96
PG 11.49 ± 0.46
On the other hand, from Table 6, it appears that PG–MCC and PG–SiO2 solid dispersions prepared
by BM had negative effect on drug solubility compared with the physical mixtures. In the case of
PG–MCC, this is ascribed to water retention due to the increased MCC amorphous content induced by
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the milling process, while in the case of PG–SiO2, to retention of water by excess silanol groups present
on the surface [46,47].
Since interactions during co-milling are restricted to particle surfaces, the extend of interaction
should depend on the degree of surface melting, or the temperature increase caused by the frictional
forces relative to the polymer glass transition temperature (Tg), and also on the applied mechanical
stress. Assuming that the thermomechanical effect is controlled by the milling conditions, the efficiency
of interaction during BM should be controlled both by the similarity of molecular forces expressed as
Hansen ∆δt and the Tg of the polymer (Table 2). From Table 6, it can be seen that PG combinations
that increased its water solubility were made with HPMC, HPMCAS and PVP which have Tg less
than 162 ◦C and ∆δt less than 13.8 Mpa0.5 (Table 2). On the other hand, combinations with negative
impact on drug solubility were with MCC and SiO2 which have Tg of 143 ◦C and 250 ◦C (transition of
cristobalite into tetragonal molecular arrangement), and ∆δt of 20.4 and 3.0 Mpa0.5, respectively.
From Tables 5 and 6, it can be seen that for both solid dispersion processes, the solubility
enhancement by HPMCAS was greater than HPMC (23.21 µg/mL compared to 16.79 µg/mL for SE and
82.13 µg/mL compared to 56.68 µg/mL for BM) despite their similar chemical structure. The different
behaviour of HPMCAS should be attributed to the greater proton donation and hence, H-bonding
ability of HPMCAS (Figure 1).
3.5. Spectroscopic Analysis of PG–HPMCAS Interactions in the Liquid State
Since PG–HPMCAS dispersion demonstrated exceptional solubility increase (from 34.21 to
82.13 µg/mL, Table 6), its H-bonding performance was further investigated by spectroscopic analysis in
the liquid state (i.e., after dissolution of powders). It is possible to understand the mechanism for the
enhanced solubility of the PG–HPMCAS by tracing drug–polymer interactions in the liquid state via
spectroscopic analysis of dissolved solid dispersions. To fine tune hydrogen bonds between PG and
HPMCAS, it is important to mask any hydrogen bonds between water molecules due to the presence
of environmental moisture. Because of the strong water absorption in the infrared region, which masks
all other peaks, HPMCAS-PG solid dispersions were dissolved in D2O instead of H2O and the spectra
of the solution were then collected. As can be seen in Figure 7, there is a broad stretching vibration
at 1735 cm−1 due to the C=O group of HPMCAS. Two peaks at 1707 and 1692 cm−1 can be seen in
the PG spectrum, which belong to the free and bound C20 PG carbonyls, respectively. A significant
shift is seen in the spectrum of HPMCAS-PG in methanol at C3 to 1655 and 1635 cm−1 (indicated by
arrows). As it can be seen in Figure 7 (third spectrum from top), there is significant shift of the large
HPMCAS carbonyl peak from 1740 to 1728 cm−1, suggesting significant intermolecular interaction
with the drug and medium. It is also seen that the two PG peaks at 1699 and 1660 cm−1 are shifted
to a lower frequency around 1570 cm−1, indicating that H-bonding is formed among C=O groups
in the PG molecule. The position of the C=O peak at 1570 cm−1 did not change at different ratios of
H2O/D2O (data not shown), meaning that the H-bonding is formed between the molecules of PG
and HPMCAS rather than D2O, in which case, the peak position would have changed with the D2O
ratio [48]. Overall, the results of the analysis of the PG–HPMCAS spectra in the liquid state confirm
with those of the FTIR on dry dispersions for the excellent H-bonding ability of HPMCAS with PG,
which should be associated with the excess protons available for H-bonding with the carbonyl groups
of the drug.
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3.6. Flory–Huggins Thermodynamic Analysis of PG–HPMCAS Interactions
Further confirmation of the miscibility of PG and HPMC is exploited by analysis of the melting
endotherms. As can be seen in Figure 8a, significant m.p. depression and heat of fusion reduction of
PG–HPMCAS physical mixtures occur as the polymer content increases. The balance between the
heat of fusion, melting point and ratio of the drug to the polymer govern the overall mixing tendency
within the formed solid dispersion. The thermodynamic treatment showed negative free energy of
mixing which was associated with a positive enthalpy (Figure 8b). This trend signifies miscibility.
The drop in the enthalpy of mixing required high polymer ratio (90%) (Figure 8b), which reflects the
high energy that holds the crystalline structure of PG together. Due to relatively higher Tg of PVP and
HPMC (150–170 ◦C), application of this thermodynamic treatment was not possible. Similarly, MCC is
partly crystalline while silica exhibits high Tg which makes assessment by this approach inappropriate.
Therefore, the thermodynamic approach adds further support for the favourable interaction of the
drug with HPMCAS.
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4. Conclusions 
The vast number of publications on solid dispersions signifies the unambiguous importance of 
this promising strategy for improvement of drug solubility. Different methods including state of the 
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co-milling has shown great potential to enhance the solubility of the drug despite the fact that the 
produced particles were not completely amorphous. The results of the present work suggest that 
prediction of solid miscibility of polymers with the drug can be made using thermal analysis and 
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4. Conclusions
The vast number of publications on solid dispersions signifies the unambiguous importance
of this promising strategy for improvement of drug solubility. Different methods including state
of the art are exploited aiming at effective and reproducible formulations. Among these methods,
mechano-chemical method is gaining ground due to the feasibility of application in real industrial
production. In this context, it is interesting that the results of the present work proved HPMCAS as
the best candidate among other polymers, and co-milling as the better method for the preparation of
solid dispersion of PG with highest solubility. Ample evidence for the drug–polymer miscibility was
provided by the thermodynamic analysis using both Hansen solubility parameters and Flory–Huggins
thermodynamics of mixing, in particular with HPMCAS. Mechano-chemical activation by co-milling
has shown great potential to enhance the solubility of the drug despite the fact that the produced
particles were not completely amorphous. The results of the present work suggest that prediction
of solid miscibility of polymers with the drug can be made using thermal analysis and vibration
spectroscopy. The results of the work can be a useful guide in the preparation of PG solid dispersions
with minimal batch-to-batch variations and enhanced drug solubility.
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